Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - Other
Status
Authorised, recruiting
Participants planned
10
Countries
1
Sites
1
Immune mediated inflammatory diseases
Key facts
- Sponsor
- Citryll B.V.
- Participant type
- Healthy volunteers
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Immune System Diseases [C20]
- Trial duration
- 26 May 2026 → ongoing
- Decision date (initial)
- 2026-05-22
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
External identifiers
- EU CT number
- 2026-526153-34-00
- ClinicalTrials.gov
- NCT07499908
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Immune mediated inflammatory diseases
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Citryll B.V.
- Sponsor organisation
- Citryll B.V.
- Address
- Rk Gebouw, Kloosterstraat 9 Kloosterstraat 9
- City
- Oss
- Postcode
- 5349 AB
- Country
- Netherlands
Scientific contact point
- Organisation
- Citryll B.V.
- Contact name
- Maarten Kraan
Public contact point
- Organisation
- Citryll B.V.
- Contact name
- Nicole Keijzer
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Netherlands | Authorised, recruiting | 10 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Pharmaceutical Research Associates Group B.V.
N/A, Van Swietenlaan 6, 9728 NZ, Groningen
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Netherlands | 2026-05-26 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-04-03 | Netherlands | Acceptable 2026-05-22
|
2026-05-22 |